Documentos relacionados

1. [The relevance of multiple sclerosis drugs in private health insurance (PHI)].
2. Reporting treatment outcomes in observational data: A fine balance.
3. Multiple sclerosis disease modifying medicine utilisation in Australia.
4. Increasing use of disease modifying drugs for MS in Canada.
5. Melatonin and vitamin D, two sides of the same coin, better to land on its edge to improve multiple sclerosis.
6. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
7. Socioeconomic consequences of multiple sclerosis-A systematic literature review.
8. Patients' preferences and willingness-to-pay for disease-modifying therapies.
9. Economic costs incurred by the patients with multiple sclerosis at different levels of the disease: a cross-sectional study in Northwest Iran.
10. Reducing costs while enhancing quality of care in MS.